Wells Fargo & Company Apellis Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

  • $434 Billion
  • Q3 2024

A detailed history of Wells Fargo & Company transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 139,368 shares of APLS stock, worth $4.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
139,368
Previous 160,228 13.02%
Holding current value
$4.55 Million
Previous $6.15 Million 34.61%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$28.84 - $41.15 $601,602 - $858,389
-20,860 Reduced 13.02%
139,368 $4.02 Million
Q2 2024

Aug 13, 2024
BUY
$38.07 - $59.71 $578,397 - $907,174
15,193 Added 10.48%
160,228 $6.15 Million
Q1 2024

May 10, 2024
BUY
$55.39 - $72.47 $690,602 - $903,555
12,468 Added 9.41%
145,035 $8.53 Million
Q4 2023

Feb 09, 2024
SELL
$37.14 - $64.82 $859,419 - $1.5 Million
-23,140 Reduced 14.86%
132,567 $7.94 Million
Q3 2023

Nov 13, 2023
BUY
$23.65 - $89.22 $1.5 Million - $5.67 Million
63,512 Added 68.89%
155,707 $5.92 Million
Q2 2023

Aug 15, 2023
SELL
$76.68 - $93.31 $1.03 Million - $1.25 Million
-13,423 Reduced 12.71%
92,195 $8.4 Million
Q1 2023

May 12, 2023
BUY
$46.59 - $66.96 $4.13 Million - $5.94 Million
88,673 Added 523.3%
105,618 $6.97 Million
Q4 2022

Feb 13, 2023
SELL
$43.24 - $61.04 $114,715 - $161,939
-2,653 Reduced 13.54%
16,945 $876,000
Q3 2022

Nov 14, 2022
BUY
$44.76 - $69.66 $169,908 - $264,429
3,796 Added 24.02%
19,598 $1.34 Million
Q2 2022

Aug 12, 2022
SELL
$35.07 - $59.21 $898,388 - $1.52 Million
-25,617 Reduced 61.85%
15,802 $714,000
Q1 2022

May 16, 2022
SELL
$35.46 - $54.12 $798,062 - $1.22 Million
-22,506 Reduced 35.21%
41,419 $2.11 Million
Q4 2021

Feb 14, 2022
BUY
$30.74 - $49.16 $409,948 - $655,597
13,336 Added 26.36%
63,925 $3.02 Million
Q3 2021

Nov 15, 2021
BUY
$31.4 - $69.84 $451,846 - $1 Million
14,390 Added 39.75%
50,589 $1.67 Million
Q2 2021

Aug 16, 2021
BUY
$40.9 - $64.9 $1.07 Million - $1.7 Million
26,162 Added 260.66%
36,199 $2.29 Million
Q1 2021

May 13, 2021
SELL
$40.8 - $57.39 $1.57 Million - $2.2 Million
-38,386 Reduced 79.27%
10,037 $430,000
Q4 2020

Feb 09, 2021
BUY
$30.79 - $57.2 $676,117 - $1.26 Million
21,959 Added 82.98%
48,423 $2.77 Million
Q3 2020

Nov 05, 2020
SELL
$25.89 - $33.65 $365,981 - $475,676
-14,136 Reduced 34.82%
26,464 $799,000
Q2 2020

Aug 13, 2020
BUY
$24.8 - $38.49 $243,734 - $378,279
9,828 Added 31.94%
40,600 $1.33 Million
Q1 2020

May 14, 2020
BUY
$17.91 - $44.33 $551,126 - $1.36 Million
30,772 New
30,772 $825,000

Others Institutions Holding APLS

# of Institutions
309
Shares Held
115M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.58B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email